文献速递临床试验与 GCP真实世界研究与卫生经济

大型制药公司临床试验数据共享与结果报告实践:横断面描述性研究及改进公司实践工具的试点

Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
PubMed 文献 · BMJ · 2019-07-10

该横断面描述性研究开发并试点了一套测量工具,评估2015年获美国食品药品监督管理局批准新药的大型制药公司的临床试验数据共享政策与实践。仅25%的公司完全符合数据共享标准,中位得分为63%;经反馈和排名工具干预后,完全符合比例升至33%,中位得分升至80%。其他透明度指标较高,但部分公司仍有较大改进空间。

要点

  • 仅25%大型制药公司完全达到参与者水平临床试验数据可及性标准。
  • 反馈与排名工具使完全符合比例从25%升至33%,中位得分从63%升至80%。
  • 新药审批后6个月内中位100%试验注册、65%报告结果、45%发表、95%以某种形式公开。

核心结论

  • 开发测量大型公司数据共享政策与实践的工具并产生改进影响是可行的。
  • 25%的大型公司按照本研究标准使参与者水平试验数据可被外部研究者获取,应用排名工具后该比例升至33%。
  • 其他试验透明度指标较高,但部分公司在临床试验透明度与数据共享方面仍有较大改进空间。

研究设计与样本

  • 横断面描述性分析,研究对象为2015年获美国食品药品监督管理局批准新药的大型制药公司。
  • 数据共享测量指标改编自专家机构的10项知名数据共享指南,并经多利益相关方审议过程完善。
  • 数据来源包括ClinicalTrials.gov、Drugs@FDA、公司网站、数据共享平台与登记库(如耶鲁开放数据访问(YODA)项目和临床研究数据请求(CSDR))以及与制药公司的个人沟通。

主要发现

  • 仅25%的大型制药公司完全满足数据共享测量标准,公司数据共享得分中位数为63%(四分位距58-85%)。
  • 给予反馈和改进政策机会后,三家公司做出修订,完全符合比例升至33%,中位得分升至80%(73-100%)。
  • 公司未初始满足数据共享测量标准的最常见原因是未在指定截止日期前共享数据(75%)和未报告数据请求的数量与结果。
  • 在新药申请中,患者试验注册中位数为100%(四分位距91-100%),报告结果中位数为65%(36-96%),发表中位数为45%(30-84%),美国食品药品监督管理局药物批准后6个月内以某种形式公开可及中位数为95%(69-100%)。
  • 在药物水平审查中,不到一半(42%)的审查药物在美国食品药品监督管理局批准后6个月内所有患者新药申请试验结果以某种形式公开可及。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop and pilot a tool to measure and improve pharmaceutical companies' clinical trial data sharing policies and practices. DESIGN: Cross sectional descriptive analysis. SETTING: Large pharmaceutical companies with novel drugs approved by the US Food and Drug Administration in 2015. DATA SOURCES: Data sharing measures were adapted from 10 prominent data sharing guidelines from expert bodies and refined through a multi-stakeholder deliberative process engaging patients, industry, academics, regulators, and others. Data sharing practices and policies were assessed using data from ClinicalTrials.gov, Drugs@FDA, corporate websites, data sharing platforms and registries (eg, the Yale Open Data Access (YODA) Project and Clinical Study Data Request (CSDR)), and personal communication with drug companies. MAIN OUTCOME MEASURES: Company level, multicomponent measure of accessibility of participant level clinical trial data (eg, analysis ready dataset and metadata); drug and trial level measures of registration, results reporting, and publication; company level overall transparency rankings; and feasibility of the measures and ranking tool to improve company data sharing policies and practices. RESULTS: Only 25% of large pharmaceutical companies fully met the data sharing measure. The median company data sharing score was 63% (interquartile range 58-85%). Given feedback and a chance to improve their policies to meet this measure, three companies made amendments, raising the percentage of companies in full compliance to 33% and the median company data sharing score to 80% (73-100%). The most common reasons companies did not initially satisfy the data sharing measure were failure to share data by the specified deadline (75%) and failure to report the number and outcome of their data requests. Across new drug applications, a median of 100% (interquartile range 91-100%) of trials in patients were registered, 65% (36-96%) reported results, 45% (30-84%) were published, and 95% (69-100%) were publicly available in some form by six months after FDA drug approval. When examining results on the drug level, less than half (42%) of reviewed drugs had results for all their new drug applications trials in patients publicly available in some form by six months after FDA approval. CONCLUSIONS: It was feasible to develop a tool to measure data sharing policies and practices among large companies and have an impact in improving company practices. Among large companies, 25% made participant level trial data accessible to external investigators for new drug approvals in accordance with the current study's measures; this proportion improved to 33% after applying the ranking tool. Other measures of trial transparency were higher. Some companies, however, have substantial room for improvement on transparency and data sharing of clinical trials.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Miller J, Ross JS, Wilenzick M, et al. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ. 2019. PMID: 31292127. doi:10.1136/bmj.l4217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。